Novo Nordisk
Novo strikes up personalised diabetes treatment deal with Glooko
January 16, 2017Sales and Marketing Glooko, Novo Nordisk, ibm
Novo Nordisk has entered into a partnership with Californian firm Glooko to develop a number of offerings to aid with …
Sanofi files lawsuit against Novo Nordisk over ‘false allegations’
January 3, 2017Manufacturing and Production, Sales and Marketing Novo Nordisk, Sanofi
Sanofi has sued Novo Nordisk over claims made in an advertising campaign for its drug Tresiba. Sanofi has filed the …
Fluor wins $2 billion Novo contract to build API manufacturing facility
December 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Fluor, Novo Nordisk, north carolina
Fluor Corporation has won an engineering, procurement and construction management contract for Novo Nordisk’s $2 billion diabetes active pharmaceutical ingredient …
Novo pledges single-digit cap on drug price hikes
December 7, 2016Medical Communications, Research and Development, Sales and Marketing Jakob Riis, Novo Nordisk
Novo Nordisk US chief Jakob Riis (pictured) has announced the insulin giant’s commitment to limit its price increases to single-digit …
Ablynx secures first €1m milestone payment from Novo Nordisk
December 5, 2016Sales and Marketing Ablynx, Novo Nordisk, nanobody
Ablynx has secured €1 million from Novo Nordisk as it hits its first discovery milestone for its multi-specific nanobody construct, …
Sanofi and Novo to face off in diabetes sphere following FDA approvals
November 22, 2016Manufacturing and Production, Sales and Marketing FDA, Novo Nordisk, Sanofi, Soliqua, Xultophy, diabetes
Sanofi and Novo are set to face off in the diabetes market after the FDA approved combination treatments from the …
Novo Nordisk to cut 2% of its entire workforce
September 29, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Denmark, Novo Nordisk, diabetes, insulin, job cuts, job losses
Novo Nordisk, headquartered in Bagsvaerd, Denmark, has taken the decision to lose 1,000 of its workforce from a total global …
Novo Nordisk to provide discounted insulin to poorest nations
September 23, 2016Medical Communications, Sales and Marketing Novo Nordisk, diabetes, insulin
Danish pharma firm Novo Nordisk has announced its intention to provide insulin at discounted prices to the world’s poorest nations …
Novo Nordisk’s diabetes drug “significantly reduced’ cardiovascular risk
September 16, 2016Medical Communications Novo Nordisk, diabetes, semaglutide
Novo Nordisk has announced that its diabetes drug semaglutide “significantly reduced” the risk of major cardiovascular events at the 52nd …
Top ten stories in the pharmaceutical industry this week
September 9, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, BMS, Celgene, Cloud Computing, Eisai, FDA, GSK, Halaven, Novartis, Novo Nordisk, Roche, Teva, agios, epipen, rheumatoid arthritis
It’s Friday, and that means it’s time for another run-down of the biggest stories on Pharmafile.com over the last week. …
Lars Rebien Sørensen to retire as CEO of Novo Nordisk
September 1, 2016Novo Nordisk, appointment
Novo Nordisk has announced that its president and CEO Lars Rebian Sørensen (pictured) is to retire at the end of …
Novo Nordisk diabetes drug Victoza fails to reduce heart failure risk
August 5, 2016Medical Communications, Research and Development Eli Lily, Novo Nordisk, Victoza, diabetes, heart failure
Novo Nordisk’s diabetes drug Victoza (liraglutide), which was found to cut cardiovascular risks in sufferers of heart disease, has failed …
Novo Nordisk says its insulin pump secures EMA marketing authorisation
June 28, 2016Manufacturing and Production, Research and Development, Sales and Marketing EMA, Novo Nordisk, insulin pump, marketing, product launch
Diabetes drugmaker Novo Nordisk (NYSE: NYO) said it has secured European Medicines Agency (EMA) marketing approval for its insulin pump. …
Novo Nordisk says Victoza lowers risk of heart attacks in diabetes patients
June 14, 2016Manufacturing and Production, Research and Development Novo Nordisk, Victoza, drug trial, type 2 diabetes
Danish diabetes drugmaker giant Novo Nordisk (NYSE: NVO) on Tuesday said a large study showed its Victoza (liraglutide) reduced the risk of …
Novo Nordisk presents Tresiba data showing significantly lower hypoglycaemia rates
June 13, 2016Research and Development, Sales and Marketing Novo Nordisk, Tresiba
Novo Nordisk (CPH: NOVO-B) has presented new Phase IIIb data on Tresiba (insulin degludec) at the American Diabetes Association annual …
